Analysts Expect Chimerix Inc (CMRX) Will Post Quarterly Sales of $850,000.00

Chimerix logo Analysts predict that Chimerix Inc (NASDAQ:CMRX) will post $850,000.00 in sales for the current fiscal quarter, according to Zacks . Four analysts have made estimates for Chimerix’s earnings, with estimates ranging from $370,000.00 to $1.65 million. Chimerix posted sales of $1.84 million in the same quarter last year, which suggests a negative year over year growth rate of 53.8%. The firm is expected to report its next quarterly earnings report on Thursday, March 7th.

On average, analysts expect that Chimerix will report full year sales of $3.03 million for the current financial year, with estimates ranging from $2.35 million to $4.00 million. For the next financial year, analysts anticipate that the business will report sales of $10.57 million, with estimates ranging from $2.72 million to $25.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that cover Chimerix.

A number of equities analysts have recently issued reports on CMRX shares. Zacks Investment Research raised Chimerix from a “hold” rating to a “buy” rating and set a $3.50 price target on the stock in a research report on Wednesday, November 14th. ValuEngine raised Chimerix from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Chimerix in a research report on Wednesday, February 6th. Two equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $6.17.

Several large investors have recently made changes to their positions in the company. BlackRock Inc. raised its position in Chimerix by 1.7% during the second quarter. BlackRock Inc. now owns 3,496,177 shares of the biopharmaceutical company’s stock valued at $16,643,000 after acquiring an additional 59,554 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Chimerix by 7.1% during the second quarter. Dimensional Fund Advisors LP now owns 2,481,614 shares of the biopharmaceutical company’s stock valued at $11,812,000 after acquiring an additional 164,472 shares in the last quarter. Millennium Management LLC raised its position in Chimerix by 12.3% during the second quarter. Millennium Management LLC now owns 284,624 shares of the biopharmaceutical company’s stock valued at $1,355,000 after acquiring an additional 31,091 shares in the last quarter. Acadian Asset Management LLC raised its position in Chimerix by 39.5% during the third quarter. Acadian Asset Management LLC now owns 216,288 shares of the biopharmaceutical company’s stock valued at $841,000 after acquiring an additional 61,221 shares in the last quarter. Finally, Leisure Capital Management purchased a new position in Chimerix during the third quarter valued at approximately $108,000. Hedge funds and other institutional investors own 73.10% of the company’s stock.

CMRX stock traded up $0.02 during midday trading on Thursday, reaching $1.99. The company’s stock had a trading volume of 252,104 shares, compared to its average volume of 284,603. Chimerix has a 1 year low of $1.95 and a 1 year high of $5.94. The firm has a market cap of $100.94 million, a price-to-earnings ratio of -1.32 and a beta of 1.39.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company’s lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.

See Also: What is a back-end load?

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Chimerix Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Chimerix and related companies with MarketBeat.com’s FREE daily email newsletter .

Tags:

Click Here to Continue...


Add a Comment

Your email address will not be published. Required fields are marked *